Broadly neutralizing monoclonal antibodies for HIV prevention.
Maurine D MinerLawrence CoreyDavid C MontefioriPublished in: Journal of the International AIDS Society (2021)
Iterative phase 1 trials are acquiring safety and pharmacokinetic data on dual and triple bnAbs and bi- and trispecific antibodies in preparation for future AMP studies that seek to translate findings from the VRC01 efficacy trials and achieve acceptable levels of overall prevention efficacy.